Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
BMJ Case Rep. 2021 Jan 26;14(1):e237501. doi: 10.1136/bcr-2020-237501.
The use of artemisinin derivatives has been recommended by the WHO guidelines in malaria treatment largely due to its rapid parasite clearance and safety profile. This case report details the development of delayed haemolysis and subsequent severe acute kidney injury (AKI) 13 days after commencing intravenous artesunate treatment for malaria in an Australian returned traveller. Delayed haemolysis may be an under-recognised complication following artesunate use and if severe, can be complicated by AKI. Therefore, close patient follow-up following treatment is required to ensure prompt recognition of this phenomenon.
世卫组织指南在疟疾治疗中推荐使用青蒿素衍生物，主要是因为它能迅速清除寄生虫和具有良好的安全性。本病例报告详细介绍了一名澳大利亚归国旅行者在接受青蒿琥酯静脉治疗疟疾 13 天后发生迟发性溶血和随后发生严重急性肾损伤（AKI）的情况。迟发性溶血可能是青蒿琥酯使用后的一种未被充分认识的并发症，如果严重，可并发 AKI。因此，需要对患者进行密切随访，以确保及时发现这种现象。
